基本信息
浏览量:1136
职业迁徙
个人简介
Professor Ching-Lung Lai has applied himself to further the understanding and the treatment of chronic hepatitis B and its complications for over three decades. His studies and clinical trials have contributed significantly to advance the development of knowledge concerning the hepatitis B virus. He performed the first trial of interferon alpha in hepatitis B carrier children in 1987. He was one of the pioneering investigators in the use of nucleoside analogues, including phase 2 and 3 studies of lamivudine (1998), telbivudine (2007) and entecavir (2006). The phases III trials of these three antiviral agents were all published in the New England Journal of Medicine. He was amongst the first to appreciate that nucleoside analogues have to be taken on a long-term basis for continuing viral suppression. This is based on the results on studies of the natural history of his research group: that the majority of complications of chronic hepatitis B occur after HBeAg seroconversion because of continued viral replication. He re-defined the treatment endpoints for chronic hepatitis B; these findings were first presented in the State-of-the-Art Lecture in the AASLD in 2005 where he received a prolonged standing ovation. He has been invited to write the editorial for the phase 3 study of tenofovir (2008)
He and his research group have also carried out studies on the natural history of hepatocellular carcinoma and its treatment starting from 1979 onwards, occult hepatitis B and its implications as well as the long-term follow-up of hepatitis B vaccine recipients. He is still continuing with his research on hepatitis B, notably the use of newer treatment agents such as besifovir and the effect of long-term treatment on the levels of cccDNA in the hepatocytes.
He and his research group have also carried out studies on the natural history of hepatocellular carcinoma and its treatment starting from 1979 onwards, occult hepatitis B and its implications as well as the long-term follow-up of hepatitis B vaccine recipients. He is still continuing with his research on hepatitis B, notably the use of newer treatment agents such as besifovir and the effect of long-term treatment on the levels of cccDNA in the hepatocytes.
研究兴趣
论文共 818 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Kristy Kwan-Shuen Chan, Tsz-Chun Hon,Kwan-Yung Au, Hiu-Lam Choi,Danny Ka-Ho Wong,Albert Chi-Yan Chan,Man-Fung Yuen,Ching-Lung Lai, Regina Cheuk-Lam Lo
Frontiers in drug discovery (2022)
Backis A.,Khaplanov A.,Jebali R. Al, Ammer R., Apostolidis I.,Birch J.,Lai C. -C.,Deen P. P.,Etxegarai M., de Ruette N., Ramos J. Freita,Förster D. F.,
Jose´ M. Morales, Paul Martin,Mengyang Di,Amy Earley,Craig E. Gordon,Ethan M. Balk,Marcelo O. Silva,Stanislas Pol,Priti R. Patel,Michel Jadoul,Ching-Lung Lai,Bertram L. Kasiske,
KIDNEYSno. 4 (2021): 261-268
BIOMEDICINESno. 8 (2021): 966-966
引用14浏览0引用
14
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn